Royalty Pharma plc Payments to Noncontrolling Interests
Royalty Pharma plc (RPRX) reported Payments to Noncontrolling Interests of $74.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToMinorityShareholders · last filed 2026-08-05
- Royalty Pharma plc payments to noncontrolling interests for the quarter ending 2026-06-30 was $34.59M, a 10.39% decline year-over-year.
- Royalty Pharma plc payments to noncontrolling interests for the quarter ending 2026-03-31 was $39.88M, a 25.92% decline year-over-year.
- Royalty Pharma plc payments to noncontrolling interests for the quarter ending 2025-12-31 was $40.76M, a 29.60% increase year-over-year.
- Royalty Pharma plc payments to noncontrolling interests for the quarter ending 2025-09-30 was $34.28M, a 10.52% increase year-over-year.
- Royalty Pharma plc payments to noncontrolling interests for fiscal 2025 was $167.47M, a 33.81% increase from fiscal 2024.
- Royalty Pharma plc payments to noncontrolling interests for fiscal 2024 was $125.16M, a 4.71% increase from fiscal 2023.
- Royalty Pharma plc payments to noncontrolling interests for fiscal 2023 was $119.53M, a 17.06% decline from fiscal 2022.
- Royalty Pharma plc payments to noncontrolling interests for fiscal 2022 was $144.12M, a 8.01% increase from fiscal 2021.
| Period end | Payments to Noncontrolling Interests 3 month | Payments to Noncontrolling Interests 3 month as first filed | Payments to Noncontrolling Interests 6 month | Payments to Noncontrolling Interests 6 month as first filed | Payments to Noncontrolling Interests 9 month | Payments to Noncontrolling Interests 9 month as first filed | Payments to Noncontrolling Interests 12 month | Payments to Noncontrolling Interests 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $74.47M 10-Q · filed 2026-08-05 | $115.23M derived: sum of 3 quarters · filed 2026-08-05 | $149.51M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $39.88M 10-Q · filed 2026-05-06 | $80.64M derived: sum of 2 quarters · filed 2026-05-06 | $114.92M derived: sum of 3 quarters · filed 2026-05-06 | $153.52M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $75.04M derived: sum of 2 quarters · filed 2026-02-11 | $113.64M derived: sum of 3 quarters · filed 2026-08-05 | $167.47M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $34.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $72.89M derived: sum of 2 quarters · filed 2026-08-05 | $126.72M 10-Q · filed 2025-11-05 | $158.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $38.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $92.44M 10-Q · filed 2026-08-05 | $123.89M derived: sum of 3 quarters · filed 2026-08-05 | $154.90M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $53.83M 10-Q · filed 2026-05-06 | $85.28M derived: sum of 2 quarters · filed 2026-05-06 | $116.30M derived: sum of 3 quarters · filed 2026-05-06 | $146.98M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $31.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $62.47M derived: sum of 2 quarters · filed 2026-02-11 | $93.15M derived: sum of 3 quarters · filed 2026-02-11 | $125.16M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $31.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $61.70M derived: sum of 2 quarters · filed 2025-11-05 | $93.71M 10-Q · filed 2025-11-05 | $118.20M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $30.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $62.69M 10-Q · filed 2025-08-06 | $87.18M derived: sum of 3 quarters · filed 2026-02-11 | $118.30M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $32.01M 10-Q · filed 2025-05-08 | $56.50M derived: sum of 2 quarters · filed 2026-02-11 | $87.62M derived: sum of 3 quarters · filed 2026-02-11 | $118.15M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $24.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $55.61M derived: sum of 2 quarters · filed 2026-02-11 | $86.14M derived: sum of 3 quarters · filed 2026-02-11 | $119.53M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $31.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $61.65M derived: sum of 2 quarters · filed 2024-11-06 | $95.05M 10-Q · filed 2024-11-06 | $128.20M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | $30.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $63.92M 10-Q · filed 2024-08-08 | $97.07M derived: sum of 3 quarters · filed 2025-02-12 | $135.69M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $33.39M 10-Q · filed 2024-05-09 | $66.55M derived: sum of 2 quarters · filed 2025-02-12 | $105.17M derived: sum of 3 quarters · filed 2025-02-12 | $142.99M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $33.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $71.77M derived: sum of 2 quarters · filed 2025-02-12 | $109.60M derived: sum of 3 quarters · filed 2025-02-12 | $144.12M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $38.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $76.45M derived: sum of 2 quarters · filed 2023-11-08 | $110.96M 10-Q · filed 2023-11-08 | $322.73M 10-Q · filed 2022-11-08 | -$119.23M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $37.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $72.34M 10-Q · filed 2023-08-08 | $215.54M 10-Q · filed 2022-08-04 | -$157.85M derived: sum of 3 quarters · filed 2024-02-15 | -$32.42M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $34.52M 10-Q · filed 2023-05-09 | $106.39M 10-Q · filed 2022-05-05 | -$195.68M derived: sum of 2 quarters · filed 2024-02-15 | -$70.25M derived: sum of 3 quarters · filed 2024-02-15 | $42.23M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | -$230.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$104.76M derived: sum of 2 quarters · filed 2024-02-15 | $7.71M derived: sum of 3 quarters · filed 2024-02-15 | $133.43M 10-K · filed 2024-02-15 | $479.60M 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $125.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $237.90M derived: sum of 2 quarters · filed 2022-11-08 | $363.62M 10-Q · filed 2022-11-08 | $76.21M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-06-30 | $112.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $238.20M 10-Q · filed 2022-08-04 | -$49.22M derived: sum of 3 quarters · filed 2023-02-15 | $67.13M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | $125.72M 10-Q · filed 2022-05-05 | -$161.69M derived: sum of 2 quarters · filed 2023-02-15 | -$45.34M derived: sum of 3 quarters · filed 2023-02-15 | $77.81M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$287.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$171.06M derived: sum of 2 quarters · filed 2023-02-15 | -$47.91M derived: sum of 3 quarters · filed 2023-02-15 | $113.48M 10-K · filed 2023-02-15 | $543.95M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $116.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $239.51M derived: sum of 2 quarters · filed 2021-11-10 | $400.89M 10-Q · filed 2021-11-10 | $437.92M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $123.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $284.55M 10-Q · filed 2021-08-11 | $321.57M derived: sum of 3 quarters · filed 2022-02-15 | $360.77M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | $161.39M 10-Q · filed 2021-05-11 | $198.41M derived: sum of 2 quarters · filed 2022-02-15 | $237.61M derived: sum of 3 quarters · filed 2022-02-15 | |||||
| 2019-12-31 | $37.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $76.23M derived: sum of 2 quarters · filed 2022-02-15 | $154.08M 10-K · filed 2022-02-15 | |||||
| 2019-09-30 | $39.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $117.06M 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | $77.86M 10-Q · filed 2020-08-12 | |||||||
| 2018-12-31 | $268.69M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |